title: Highly selective inhibition of human CYP3Aa in vitro by azamulin and evidence that inhibition is irreversible.
abstract: Azamulin [14-O-(5-(2-amino-1,3,4-triazolyl)thioacetyl)-dihydromutilin] is an azole derivative of the pleuromutilin class of antiinfectives. We tested the inhibition potency of azamulin toward 18 cytochromes P450 using human liver microsomes or microsomes from insect cells expressing single isoforms. In a competitive inhibition model, IC(50) values for CYP3A (0.03-0.24 microM) were at least 100-fold lower than all other non-CYP3A enzymes except CYP2J2 ( approximately 50-fold lower). The IC(50) value with heterologously expressed CYP3A4 was 15-fold and 13-fold less than those of CYP3A5 and CYP3A7, respectively. The reference inhibitor ketoconazole was less selective and exhibited potent inhibition (IC(50) values <10 microM) for CYP1A1, CYP1B1, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP4F2, and CYP4F12. Inhibition of CYP3A by azamulin appeared sigmoidal and well behaved with the substrates 7-benzyloxy-4-trifluoromethylcoumarin, testosterone, and midazolam. Preincubation of 4.8 microM azamulin in the presence of NADPH for 10 min inhibited approximately 95% of testosterone 6beta-hydroxylase activity compared with preincubation in the absence of NADPH. Catalytic activities of CYP1A2, CYP2C8, CYP2C9, CYP2C19, CYP2D6, and CYP2E1 were unaffected by similar experiments. Incubation of azamulin with heterologously expressed CYP3A4 yielded a type I binding spectrum with a spectral dissociation constant of 3.5 microM, whereas no interaction was found with CYP2D6. Azamulin exhibited good chemical stability when stored in acetonitrile for up to 12 days. Aqueous solubility was found to be >300 microM. Azamulin represents an important new chemical tool for use in characterizing the contribution of CYP3A to the metabolism of xenobiotics.
authors.affiliation: BD Biosciences, Discovery Labware, Inc., 6 Henshaw Street, Woburn, MA 01801, USA. David_Stresser@bd.com
authors.forename: David M
authors.initials: DM
authors.lastname: Stresser
authors.forename: Marc I
authors.initials: MI
authors.lastname: Broudy
authors.forename: Thuy
authors.initials: T
authors.lastname: Ho
authors.forename: Catherine E
authors.initials: CE
authors.lastname: Cargill
authors.forename: Andrew P
authors.initials: AP
authors.lastname: Blanchard
authors.forename: Raman
authors.initials: R
authors.lastname: Sharma
authors.forename: Andre A
authors.initials: AA
authors.lastname: Dandeneau
authors.forename: Joseph J
authors.initials: JJ
authors.lastname: Goodwin
authors.forename: Stephanie D
authors.initials: SD
authors.lastname: Turner
authors.forename: John C L
authors.initials: JC
authors.lastname: Erve
authors.forename: Christopher J
authors.initials: CJ
authors.lastname: Patten
authors.forename: Shangara S
authors.initials: SS
authors.lastname: Dehal
authors.forename: Charles L
authors.initials: CL
authors.lastname: Crespi
mesh_terms: D000890:Anti-Infective Agents / Q000494:pharmacology*; D001952:Bridged-Ring Compounds / Q000494:pharmacology*; D065607:Cytochrome P-450 Enzyme Inhibitors; D003577:Cytochrome P-450 Enzyme System / Q000737:chemistry; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005470:Fluorometry; D006801:Humans; D066298:In Vitro Techniques; D007654:Ketoconazole / Q000494:pharmacology; D008862:Microsomes, Liver / Q000187:drug effects / Q000201:enzymology; D009249:NADP / Q000494:pharmacology; D020076:Pleurotus / Q000187:drug effects / Q000201:enzymology; D012995:Solubility; D013250:Steroid Hydroxylases / Q000037:antagonists & inhibitors; D013379:Substrate Specificity; D014230:Triazoles / Q000494:pharmacology*; D015262:Xenobiotics / Q000378:metabolism
chemical_list: D000890:Anti-Infective Agents; D001952:Bridged-Ring Compounds; D065607:Cytochrome P-450 Enzyme Inhibitors; D004791:Enzyme Inhibitors; D014230:Triazoles; D015262:Xenobiotics; D009249:NADP; C489644:azamulin; D003577:Cytochrome P-450 Enzyme System; D013250:Steroid Hydroxylases; C022657:steroid hormone 6-beta-hydroxylase; D007654:Ketoconazole